Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Incyte’s Grip On Myelofibrosis Tightens With Release Of Positive JAK Data, FDA Filing

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

The profile and potential of Incyte Corp.’s ruxolitinib (INCB18424) in myelofibrosis came into sharper focus with the release of detailed data from two major trials at the American Society of Clinical Oncology meeting and announcement of an FDA filing.

You may also be interested in...

JAK Of All Trades: Janus Kinase Inhibitors Are Ready, Willing And Orally Available For Many Diseases

Orally available, flexible and novel, Janus kinase inhibitors are poised to trigger major treatment shakeups in at least two disease spaces. Two drugs at the head of the JAK pack are close to coming of age – Pfizer Inc.’s tofacitinib and Incyte Corp.’s ‘18424 – and hopes are high, though questions remain about selectivity, long-term side effects and just how far the class can go.

With Lilly JAK Tie-up, Incyte Aims To Chase Pfizer In Rheumatoid Arthritis

No time to lose: A deal for an earlier-stage oral drug underscores Big Pharma's passion for new targets in inflammatory diseases.

Two-Compound Partnership With Novartis Brings Incyte $210 Million Immediately

The two companies will co-develop an oral JAK1/JAK2 inhibitor in myelofibrosis and likely other indications as well.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts